Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
With
National Comprehensive Cancer Network
Wyeth is now a wholly owned subsidiary of Pfizer
The effectiveness of treatments for recurrent sarcomas is quite limited. One hypothesis to explain the refractory nature of recurrent sarcomas is the existence of chemotherapy-resistant sarcoma stem cells.
Age
1–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed sarcoma that is recurrent or refractory to conventional treatment
Measurable disease by RECIST criteria
ECOG (Eastern Cooperative Oncology Group) performance status \< 2 (or Lansky/Karnofsky \> 60% for children)
Life expectancy greater than 3 months
Adequate organ function
absolute neutrophil count at least 1,500
platelets at least 100,000
bilirubin less than 1.5 x upper limit of normal
AST (aspartate aminotransferase) and ALT(alanine aminotransferase) less than 2.5 x upper limit of normal
creatinine less than 1.5 x upper limit of normal OR creatinine clearance at least 60 ml/min/1.73 m2
fasting serum cholesterol less than 350
fasting serum triglycerides less than 400
PT (prothrombin) or INR (international normalized ratio) less than 1.3 x upper limit of normal
normal urinalysis
Ability to understand and sign the informed consent document
You may not be if
Prior chemotherapy or radiotherapy within 3 weeks of entering the study (6 weeks for nitrosoureas or mitomycin C)
Prior treatment with a tyrosine kinase inhibitor within 10 days of entering the study
History of pulmonary hypertension or pneumonitis
Patients may not be receiving other investigational agents
Prior therapy with rapamycin, rapamycin analogues, or tacrolimus
Uncontrolled brain metastases
History of grade 3 or 4 hypersensitivity to macrolide antibiotics
Concurrent treatment with immunosuppressive agents other than a stable (for more than 2 weeks) dose of corticosteroids
Uncontrolled intercurrent illness
Pregnancy or breast feeding
HIV-positive patients on combination antiretroviral therapy
Grade 3 or 4 proteinuria
Clareo Health | Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
